689299-71-6

Upstream product

• 689303-00-2 (E)-3-(4’-chloro-[1,1‘-biphenyl]-4-yl)acrylate 
• 29608-05-7 1-(4-aminobenzyl)piperidine 
• 83281-26-9 3-(4'-chloro-biphenyl-4-yl)-acrylic acid 

Downstream Products

• 858678-06-5 2,3-dibromo-3-(4'-chloro-biphenyl-4-yl)-N-(4-piperidin-1-ylmethyl-phenyl)-propionamide 

Relevant academic research and scientific papers

Design, synthesis and evaluation of MCH receptor 1 antagonists - Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition

Abstract Despite recent success there remains a high therapeutic need for the development of drugs targeting diseases associated with the metabolic syndrome. As part of our search for safe and effective MCH-R1 antagonists for the treatment of obesity, a s

3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS

The invention relates to amid compounds of general formula (I), wherein groups and residuals A, B, b, W, X, Y, Z, R1, R2 and R3 have significances given in a claim 1. In addition, said invention relates to drugs containing at least one type of inventive amid. Because of the antagonist activity of an MCH-receptor, the inventive drugs are suitable for treating metabolic disturbances and/or eating disorders, in particular adiposity, bulimia, anorexia, hyperphagia and diabetes.

NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS

The invention relates to amide compounds of general formula (I), in which the groups and residues A, B, b, W, X, Y, Z, R1, R2 and R3 have the meanings given in claim 1. The invention further relates to medicaments comprising at least one of said amides. Said medicaments are suitable for the treatment of metabolic disorders and/or eating disorders, in particular, obesity, bulimia, anorexia, hyperphagia, and diabetes as a result of the MCH receptor antagonism.